ArticleNeurochemical research2026
Modulating miRNA-367-3p Expression by Kaempferol Alleviates Experimental Autoimmune Encephalomyelitis: Targeting Fpn1-Dependent Ferroptosis and cAMP/CREB/CNTF Signaling.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a progressive, immune-mediated demyelinating disorder of the central nervous system (CNS). Kaempferol (KAM), a dietary bioflavonoid found in many edible and medicinal plants, exhibits significant neuroprotective effects in various immunological and neurological disorders; however, its therapeutic potential in MS remains largely unexplored. This study aimed to investigate the protective effects of KAM and the underlying molecular mechanisms using an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. 40 female C57B1/6 mice were assigned to 4 groups: Normal control [saline (i.d.) + DMSO (i.p.)]; KAM [saline (i.d.) + KAM (50 mg/kg/d, i.p.)]; EAE [MOG35–55 immunization (i.d.) + DMSO (i.p.)]; and EAE + KAM [MOG35–55 immunization (i.d.) + KAM (50 mg/kg/d, i.p.)]. The brain and spinal cord were dissected for biochemical, molecular, histopathological, electron microscopic, and immunohistochemical analysis. KAM administration efficiently reduced clinical scores and ameliorated neural cytomorphological abnormalities. KAM profoundly combated iron overload and effectively upregulated ferroportin1 (Fpn1)-encoding gene expression. Furthermore, KAM valuably counteracted neuronal ferroptosis chiefly by restoring the Slc7A11/GSH/GPX4 axis. KAM considerably attenuated proinflammatory cytokine IL-17 and chemokine CCL-19. Intriguingly, KAM promoted axonal remyelination as indicated by an observable escalation in myelin basic protein content through activating the cAMP/CREB/ciliary neurotrophic factor (CNTF) axis. Collectively, for the first time, these findings demonstrated KAM’s neuroprotective potency against EAE, considering its antioxidant, anti-ferroptotic, immunomodulatory, anti-inflammatory, and neurotrophic properties, primarily mediated by inhibiting Fpn1-mediated ferroptosis, activating the cAMP/CREB/CNTF axis, and enhancing miRNA-367-3p expression. Accordingly, miRNA-367-3p has been proposed as an upcoming therapeutic target for MS, and KAM could be a promising treatment option for MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.